Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoroquinolone-Based Regimens for Brucellosis (BRUCE)
NCT07779629Withdrawn
- Sponsor
- The First Affiliated Hospital of Shihezi University
- Start
- Oct 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of levofloxacin and moxifloxacin in brucellosis (6 arms), sponsored by The First Affiliated Hospital of Shihezi University. Primary endpoints: Clinical Cure Rate at 6 weeks, Recurrence Rate at 6 months and 3 more. Planned start Oct 2026; status: withdrawn.
02
Drugs
levofloxacinmoxifloxacin
03
Conditions
brucellosis
Beyond the preview
Go deeper on NCT07779629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779629.